HHS ordered to cut 35% of spending on contracts

Clinical Conversation with The Cancer Letter

Will MCD tests revolutionize cancer screening? NCI begins enrollment in Vanguard “feasibility” trial to start finding out

The first large cancer screening/early detection initiative to be launched in 2025—the NCI-funded Vanguard study of multi-cancer detection tests—has started accruing patients through nine sites across the U.S.

July 25, 2025

Vol.51 No.29

By Sara Willa Ernst, Jacquelyn Cobb and Paul Goldberg

Oncologist biotech entrepreneur George Tidmarsh joins FDA as CDER director
His appointment came out of “proximity” to Makary and Bhattacharya

In a move that will have direct impact on approval of cancer drugs, George Francis Tidmarsh, an oncologist and a longtime pharmaceutical executive, was named director of the FDA Center for Drug Evaluation and Research.

July 25, 2025

Vol.51 No.29

By Claire Marie Porter

Cancer Policy

FY25 paylines drop to 4th percentile—a historic low—as NCI braces for Trump’s FY26 budget cuts

NCI announced that the paylines for R01 grants for established and new investigators are expected to drop to the 4th percentile—a historic low for the institute.

NIH says it’s moving away from animal-based models

NIH has announced that it will no longer be issuing Notices of Funding Opportunities exclusively supporting animal models.

July 18, 2025

Vol.51 No.28

By Claire Marie Porter

Cancer Policy

CMS proposes policy to move away from hospital-based care

The Centers for Medicare & Medicaid Services issued a proposed rule that would update Medicare payment policies and rates for hospital outpatient departments and ambulatory surgical centers, or ASCs, for calendar year 2026.

July 18, 2025

Vol.51 No.28

By Claire Marie Porter

Clinical Roundup

Enrollment begins in NCI’s Vanguard study focused on defining benefits of MCD tests

NCI has initiated a pilot study to address the feasibility of using multi-cancer detection, or MCD, tests in future randomized controlled trials.

July 18, 2025

Vol.51 No.28

HHS ordered to cut 35% of spending on contracts

YOU MAY BE INTERESTED IN

Will MCD tests revolutionize cancer screening? NCI begins enrollment in Vanguard “feasibility” trial to start finding out

Oncologist biotech entrepreneur George Tidmarsh joins FDA as CDER director
His appointment came out of “proximity” to Makary and Bhattacharya

FY25 paylines drop to 4th percentile—a historic low—as NCI braces for Trump’s FY26 budget cuts

NIH says it’s moving away from animal-based models

CMS proposes policy to move away from hospital-based care

Enrollment begins in NCI’s Vanguard study focused on defining benefits of MCD tests

Renew today!

Subscriber content

Never miss an issue!

Login

HHS ordered to cut 35% of spending on contracts

YOU MAY BE INTERESTED IN

Will MCD tests revolutionize cancer screening? NCI begins enrollment in Vanguard “feasibility” trial to start finding out

Oncologist biotech entrepreneur George Tidmarsh joins FDA as CDER directorHis appointment came out of “proximity” to Makary and Bhattacharya

FY25 paylines drop to 4th percentile—a historic low—as NCI braces for Trump’s FY26 budget cuts

NIH says it’s moving away from animal-based models

CMS proposes policy to move away from hospital-based care

Enrollment begins in NCI’s Vanguard study focused on defining benefits of MCD tests

Never miss an issue!

Login

Oncologist biotech entrepreneur George Tidmarsh joins FDA as CDER director
His appointment came out of “proximity” to Makary and Bhattacharya